An unusual opportunity in therapeutics:

- later stage – a clinical company with a potential exit in 1 year
- capital efficient model & CPRIT non-dilutive backing
- Ride on the diligence already done by
  - an institutional investor (Sante Ventures led Series A)
  - CPRIT ($16 MM Award from Texas)
- Strategic follower – In JLABS, invitation only by J&J
Safe Harbor Statement

This presentation contains forward-looking statements. These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance, or achievements expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as “may,” “could,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other comparable terminology. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond our control and that could materially affect actual results, levels of activity, performance, or achievements.

If any of these risks or uncertainties materialize, or if our underlying assumptions prove to be incorrect, actual results may vary significantly from what we projected. Any forward-looking statement you read in this presentation reflects our current views with respect to future events and is subject to these and other risks, uncertainties, and assumptions relating to our operations, results of operations, growth strategy, and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, whether as a result of new information, future events, or otherwise.
Attractive Investment Opportunity – A “Holy Grail” Cancer Therapy

• Beta Cat is an oncology-focused biotechnology company
• Focused on Wnt/beta catenin
  • Makes tumors act “stemish” – Like stem cells, fast dividing and growing with no “checks”
  • “Stemish”, causes cancer spread and resists the treatments we have
• Lead drug, Tegavivint, focuses in areas with high unmet need
  ▪ Main commercial potential – late stage cancers in combo
  ▪ Capital efficient to market strategy – orphan cancers
• IND filing November 2017 (FDA approval for clinical trials)
• Clinical trials start January, 2018; readout by end of year
Broad Potential

Commercialization Focus: Major Tumors & Fibrosis

Combo Potential - Cancer

- Colon
- Breast
- Lung
- Melanoma
- Prostate
- Acute Myeloid Leukemia
- Multiple Myeloma

Wnt/ Beta Catenin Cancers

Over 400,000 new patients per year need this therapy (USA alone)
Orphan Registration gives quick time to exit Tegavivint, Cures Human Osteosarcoma Tissue Implanted in Mice

No approved therapy for osteosarcoma; Lung metastasis is most common reason for death

Companion canine trial (genetically very similar to human) going on now
Tegavivent and Trametinib (MEK inhibitor) are synergistic in a colon cancer animal model

CT26 murine colon cancer cells were implanted into Balb/c mice and allowed to grow to establish. Animals were treated with Tegavivent and Trametinib every day for 14 days.
Beta Cat Lead Drug, Tegavivint (BC2059), Provides Survival in Models of Leukemia Resistant to Current Therapies, with only Minimal Drug Doses

Treatment 2x Per Week, for 3 Weeks; Only 6 Total Doses of Tegavivint (BC2059)
WNT Pathway – No competition in development

• **Discovered in 1982 by Nusse and Varmus**
  - Received a Nobel Prize for this Fundamental growth control pathway
  - Dysregulated in many cancers and fibrotic diseases

• **Many have tried, as it turns out, prematurely**
  - First drug efforts on nuclear and cytoplasmic targets unsuccessful
  - Second efforts with antibodies, ADCs, and fusion proteins unsuccessful

• **A new target, a second checkpoint in pathway, discovered 2008**
  - **TBL1** – Transducin Beta Like Protein 1
  - Sports a deep druggable hydrophobic pocket, first in the pathway

• **Beta Cat’s Tegavivint (BC-2059) uses this newly discovered biology**
Proficient Team with Talent Attracted from Across the US & Abroad

Jon Northrup, MBA, CLP  
Co-Founder & Chief Executive Officer  
- Board Member – Salarius Pharma, Sting Ray Therapeutics, Convergene  
- SVP Corp. Bus. Dev. – Eli Lilly  
- Director, Sales & Marketing – Eli Lilly  
- COO – Jubilant Innovation VC  
- Author – The Business of Healthcare Innovation

Casey Cunningham, MD  
Chief Medical Officer  
- Sante Ventures – CSO;  
- Mark Crowley Cancer Research Center – Assoc. Dir.;  
- Operating Roles in Many Startups & Biotechs; Harvard MD, Oncology-Hematology

Stephen Horrigan, PhD  
Chief Scientific Officer  
- Noble Life Sciences – CSO; 20+ Years Cancer Drug Development  
- Avalon Pharma – CSO; Molecular Geneticist;  
- Georgetown – Associate Professor

Scott Jordan, MBA  
Chief Financial Officer  
- 25+ years of life sciences experience in banking/finance.  
- HealthiosXchange -co-founder;  
Healthios Capital Markets – VP, Abbott Labs.

Neil Sankar, MD, MPH  
Medical Director & Monitor  
- Senior roles with Genentech, Pharmacicles, Medimmune, Five Prime, Loxo Oncology, Portola, CBT and National Cancer Institute  
- Clinical lead for 2 successful IND’s in oncology

Jeff Larson, Ph.D., DABT  
VP, Nonclinical Development  
- 20+ years of pharmaceutical & pre-clinical development experience  
- Texas Bioalliance – VP; Parady Consulting – President; Wildcat Venture Mgmt – VP; NexBio – AVP; Tanox – Sr. Dir.

Rose Hernandez,  
Clinical Operations Director  
- 17 years of global clinical research experience  
- Brain Sentinel - Sr. Director Medial Affairs & Regulatory Compliance;  
- CeloNova – Director Clinical Affairs

Srinivas Kasibhatla, Ph.D.  
VP, Medicinal Chemistry  
- 25+ years drug discovery. Contributed to discovery of 9 clinical candidates.

Raffaella Soldi, Ph.D.  
Director of Biology  
- 25 years of translational medicine experience.

Uma Bhatt, CPA  
Chief Accounting Officer, Controller  
- 26 years experience in accounting  
- CFO/COO Ham-Let USA and Canada  
- BG Group, Director of Finance  
- Halliburton / HBP BILLITON

Neil Sankar, MD, MPH  
Medical Director & Monitor  
- Senior roles with Genentech, Pharmacicles, Medimmune, Five Prime, Loxo Oncology, Portola, CBT and National Cancer Institute  
- Clinical lead for 2 successful IND’s in oncology

Raffaella Soldi, Ph.D.  
Director of Biology  
- 25 years of translational medicine experience.
Business Plan – Expedited Timeline to Exit with Minimal Dilution to Investors

• Top of the “Leader Board” with Food & Drug Administration
  • Orphan Drug
  • Breakthrough Status/Accelerated Approval
  • Fast Track Status

• Non-Dilutive $16M funding award from the State of Texas
  • Cancer Prevention and Research Institute of Texas (CPRIT)

• Investors ride on coattails of diligence performed by premier institutions
  • Sante Ventures – Austin, TX Institutional VC
  • Johnson & Johnson – Strategic interest
  • CPRIT

• Robust IP with Long Runway – Composition of matter issued in U.S. and most countries
  • Estimated expirations 2028 to 2037 plus extensions
Timeline & Exit Strategy

<table>
<thead>
<tr>
<th>2017</th>
<th>2018</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q1</td>
<td>Q1</td>
<td>Q1</td>
</tr>
<tr>
<td>Q2</td>
<td>Q2</td>
<td>Q2</td>
</tr>
<tr>
<td>Q3</td>
<td>Q3</td>
<td>Q3</td>
</tr>
<tr>
<td>Q4</td>
<td>Q4</td>
<td>Q4</td>
</tr>
</tbody>
</table>

- **IND Prep & Submission**
- **Drug Manufacture**
- **Site Readiness - IRB Approval**

**Convertible Note Funds Through 2018**

- **Desmoid Phase I**
- **Desmoid Phase II**
- **Biomarker Driven Solid Tumor**
- **Canine Osteo**
- **Osteosarcoma Phase 1**
- **Leukemia**

**Exit Opportunity #1**
Phase 1 Human Data in Desmoid, Leukemia, & Solid Tumors

**Beta Cat is pursuing a capital efficient regulatory strategy**
- Pursue Desmoid/Osteo – fast timeline to approval
- Follow with colon/solid tumors – Large market & major pharma interest
- Capital efficient Osteo canine trial first

**Two Potential exits for investors:**
1. Big Pharma Acquisition after phase 1 at end of 2018
2. Consider Series B to fund a phase 2 registration trial; exit on New Drug Application filing (2020) for later, much bigger exit
Summary: Compelling Investment Opportunity

Scientifically Attractive

• Tegavivint uniquely shuts down a major cancer pathway
• Broadly important across cancer and needed by immuno-oncology therapies in combo
• Strongly vetted technology

Financially Attractive

• CPRIT non-dilutive award
• Capital efficient model
• Deeply experienced team
• In the clinic this year – should allow for near term value inflection

Cat Pharma
Thank you for your time and interest